Dobbelstein, Matthias, Prof. Dr.
Professor of Molecular Oncology
- Dr. med., University of Munich, 1993
- Postdoctoral fellow, Princeton University, USA, 1993-1996
- Group leader, University of Marburg, 1997-2004
- 2004-2005 Professor of Molecular Oncology, University of Southern Denmark, Odense
- Head of the Department of Molecular Oncology, Georg-August-Universität Göttingen, since 2005
Major Research Interests
We are trying to understand the response of cancer cells to chemotherapy. In particular, we are analyzing the impaired replication of DNA and the damage response that results from injury to DNA. Our focus is on the signaling cascades driven by DNA damage, and on the activation of the tumor suppressor p53. Technologies include the use of large scale siRNA transfection, followed by automated fluorescence microscopy, and the analysis of DNA replication by incorporation of artificial nucleosides. As a disease model, we are investigating the response of colorectal cancer to therapy. On top of classical, DNA damaging chemotherapeutics, we are evaluating other broadly acting, yet non-genotoxic drug candidates, e. g. inhibitors of histone deacetylases and heat shock proteins. On long term, we are aiming at improving the response of tumor cells to chemotherapy by combining traditional and targeted therapeutic approaches.
Some of my lectures are available as youtube videos, at the channel mdobbelstein.
Please see http://www.youtube.com/user/mdobbelstein?feature=results_main.
Homepage Department/Research Group
Selected Recent Publications
- Zhang X, Schulz R, Edmunds S, Krüger E, Markert E, Gaedcke J, Cormet-Boyaka E, Ghadimi M, Beissbarth T, Levine AJ, Moll UM, Dobbelstein M (2015) MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP Mol Cell 59(2): 243-57
- Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R, Proia DA, Lozano G, Dobbelstein M, Moll UM (2015) Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature523(7560): 352-6
- Dobbelstein M, Sørensen CS (2015) Exploiting replicative stress to treat cancer. Nat Rev Drug Discov 14(6): 405-23
- Dobbelstein M, Moll U (2014) Targeting tumour-supportive cellular machineries in anticancer drug development. Nat Rev Drug Discov 13(3):179-96
- Köpper F, Bierwirth C, Schön M, Kunze M, Elvers I, Kranz D, Saini P, Menon M, Walter D, Sørensen CS, Gaestel M, Helleday T, Schön M P, Dobbelstein M (2013) Damage-induced DNA replication stalling relies on MAPK-activated protein kinase 2 activity. Proc Natl Acad Sci USA 110: 16856-16861
- Beyer U, Moll-Rocek J, Moll UM, Dobbelstein M (2011) Endogenous retrovirus drives hitherto unknown proapoptotic p63 isoforms in the male germ line of humans and great apes. Proc Natl Acad Sci USA 108(9): 3624-9
- Braun CJ, Zhang X, Savelyeva I, Wolff S, Moll UM, Schepeler T, Ørntoft TF, Andersen CL, Dobbelstein M (2008) p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 68(24): 10094-104